133 related articles for article (PubMed ID: 7994571)
1. Salt bridge relay triggers defective LDL receptor binding by a mutant apolipoprotein.
Wilson C; Mau T; Weisgraber KH; Wardell MR; Mahley RW; Agard DA
Structure; 1994 Aug; 2(8):713-8. PubMed ID: 7994571
[TBL] [Abstract][Full Text] [Related]
2. Novel mechanism for defective receptor binding of apolipoprotein E2 in type III hyperlipoproteinemia.
Dong LM; Parkin S; Trakhanov SD; Rupp B; Simmons T; Arnold KS; Newhouse YM; Innerarity TL; Weisgraber KH
Nat Struct Biol; 1996 Aug; 3(8):718-22. PubMed ID: 8756331
[TBL] [Abstract][Full Text] [Related]
3. Three-dimensional structure of the LDL receptor-binding domain of human apolipoprotein E.
Wilson C; Wardell MR; Weisgraber KH; Mahley RW; Agard DA
Science; 1991 Jun; 252(5014):1817-22. PubMed ID: 2063194
[TBL] [Abstract][Full Text] [Related]
4. Conformationally specific enhancement of receptor-mediated LDL binding and internalization by peptide models of a conserved anionic N-terminal domain of human apolipoprotein E.
Braddock DT; Mercurius KO; Subramanian RM; Dominguez SR; Davies PF; Meredith SC
Biochemistry; 1996 Nov; 35(44):13975-84. PubMed ID: 8909295
[TBL] [Abstract][Full Text] [Related]
5. Three-dimensional structure of the LDL receptor-binding domain of the human apolipoprotein E2 (Arg136-->Cys) variant.
Feussner G; Albanese M; Valencia A
Atherosclerosis; 1996 Oct; 126(2):177-84. PubMed ID: 8902143
[TBL] [Abstract][Full Text] [Related]
6. Apolipoprotein E;-low density lipoprotein receptor interaction. Influences of basic residue and amphipathic alpha-helix organization in the ligand.
Zaiou M; Arnold KS; Newhouse YM; Innerarity TL; Weisgraber KH; Segall ML; Phillips MC; Lund-Katz S
J Lipid Res; 2000 Jul; 41(7):1087-95. PubMed ID: 10884290
[TBL] [Abstract][Full Text] [Related]
7. A novel electrophoretic variant of human apolipoprotein E. Identification and characterization of apolipoprotein E1.
Weisgraber KH; Rall SC; Innerarity TL; Mahley RW; Kuusi T; Ehnholm C
J Clin Invest; 1984 Apr; 73(4):1024-33. PubMed ID: 6323533
[TBL] [Abstract][Full Text] [Related]
8. Molecular characterization of two monoclonal antibodies specific for the LDL receptor-binding site of human apolipoprotein E.
Raffai R; Maurice R; Weisgraber K; Innerarity T; Wang X; MacKenzie R; Hirama T; Watson D; Rassart E; Milne R
J Lipid Res; 1995 Sep; 36(9):1905-18. PubMed ID: 8558079
[TBL] [Abstract][Full Text] [Related]
9. Structure-function relationships in side chain lactam cross-linked peptide models of a conserved N-terminal domain of apolipoprotein E.
Benzinger TL; Braddock DT; Dominguez SR; Burkoth TS; Miller-Auer H; Subramanian RM; Fless GM; Jones DN; Lynn DG; Meredith SC
Biochemistry; 1998 Sep; 37(38):13222-9. PubMed ID: 9748329
[TBL] [Abstract][Full Text] [Related]
10. The receptor binding domain of apolipoprotein E, linked to a model class A amphipathic helix, enhances internalization and degradation of LDL by fibroblasts.
Datta G; Chaddha M; Garber DW; Chung BH; Tytler EM; Dashti N; Bradley WA; Gianturco SH; Anantharamaiah GM
Biochemistry; 2000 Jan; 39(1):213-20. PubMed ID: 10625496
[TBL] [Abstract][Full Text] [Related]
11. Molecular studies of pH-dependent ligand interactions with the low-density lipoprotein receptor.
Yamamoto T; Chen HC; Guigard E; Kay CM; Ryan RO
Biochemistry; 2008 Nov; 47(44):11647-52. PubMed ID: 18847225
[TBL] [Abstract][Full Text] [Related]
12. Conformational flexibility in the apolipoprotein E amino-terminal domain structure determined from three new crystal forms: implications for lipid binding.
Segelke BW; Forstner M; Knapp M; Trakhanov SD; Parkin S; Newhouse YM; Bellamy HD; Weisgraber KH; Rupp B
Protein Sci; 2000 May; 9(5):886-97. PubMed ID: 10850798
[TBL] [Abstract][Full Text] [Related]
13. A novel apolipoprotein E mutation, E2 (Arg25Cys), in lipoprotein glomerulopathy.
Matsunaga A; Sasaki J; Komatsu T; Kanatsu K; Tsuji E; Moriyama K; Koga T; Arakawa K; Oikawa S; Saito T; Kita T; Doi T
Kidney Int; 1999 Aug; 56(2):421-7. PubMed ID: 10432380
[TBL] [Abstract][Full Text] [Related]
14. Apolipoprotein E2(Arg158----Cys) frequency in a hyperlipidemic French-Canadian population of apolipoprotein E2/2 subjects. Determination by synthetic oligonucleotide probes.
Weisgraber KH; Newhouse YM; Taylor JM; Tuan B; Nestruck AC; Davignon J; Mahley RW
Arteriosclerosis; 1989; 9(1):50-7. PubMed ID: 2912421
[TBL] [Abstract][Full Text] [Related]
15. The lipid-associated conformation of the low density lipoprotein receptor binding domain of human apolipoprotein E.
Fisher CA; Narayanaswami V; Ryan RO
J Biol Chem; 2000 Oct; 275(43):33601-6. PubMed ID: 10906325
[TBL] [Abstract][Full Text] [Related]
16. Enhanced binding activity of an apolipoprotein E mutant, APO E5, to LDL receptors on human fibroblasts.
Dong LM; Yamamura T; Yamamoto A
Biochem Biophys Res Commun; 1990 Apr; 168(2):409-14. PubMed ID: 2334412
[TBL] [Abstract][Full Text] [Related]
17. Identification of the low density lipoprotein receptor-binding site in apolipoprotein B100 and the modulation of its binding activity by the carboxyl terminus in familial defective apo-B100.
Boren J; Lee I; Zhu W; Arnold K; Taylor S; Innerarity TL
J Clin Invest; 1998 Mar; 101(5):1084-93. PubMed ID: 9486979
[TBL] [Abstract][Full Text] [Related]
18. Human low density lipoprotein receptor fragment. Successful refolding of a functionally active ligand-binding domain produced in Escherichia coli.
Simmons T; Newhouse YM; Arnold KS; Innerarity TL; Weisgraber KH
J Biol Chem; 1997 Oct; 272(41):25531-6. PubMed ID: 9325268
[TBL] [Abstract][Full Text] [Related]
19. [Human apolipoprotein E: polymorphism and binding domain of the receptors].
Bekaert ED; Ayrault-Jarrier M; Polonovski J
Biochimie; 1986 May; 68(5):629-37. PubMed ID: 3015256
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a novel variant of apolipoprotein E, E2 Fukuoka (Arg-224 --> Gln) in a hyperlipidemic patient with xanthomatosis.
Moriyama K; Sasaki J; Takada Y; Arakawa F; Matsunaga A; Ito Y; Arakawa K
Biochim Biophys Acta; 1996 Jun; 1301(3):185-90. PubMed ID: 8664327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
